視錐細胞和視桿細胞營養不良市場：按疾病類型、診斷方法、治療方法、最終用戶和地區分類

預計到 2026 年，視錐細胞和視桿細胞營養不良症市值將達到 1.486 億美元，到 2033 年將達到 2.378 億美元。預計從 2026 年到 2033 年，該市場將以 7% 的複合年成長率成長。

視錐細胞-視桿細胞營養不良症（CRD）是一種罕見的遺傳性疾病，其特徵是視網膜中視錐細胞和視桿細胞逐漸退化。這會導致中心視力、色覺和視力逐漸喪失，最終導致周邊視力喪失。視錐細胞-視桿細胞營養不良症可由多種基因突變引起，涉及30多個基因，包括ABCA4、RPGR和CRX基因，其遺傳方式為體染色體顯性遺傳、隱性遺傳或X連鎖遺傳。據估計，CRD的全球盛行率為三萬分之一至四萬分之一，因此該領域的醫療需求遠未滿足。

視錐細胞和視桿細胞營養不良市場包含多個細分領域，包括診斷、支持性護理和低視力復健技術，以及基因和細胞療法。基因和細胞療法雖然仍在發展中，但正穩步推進，代表著新型和先進的治療選擇。市場成長的促進因素包括基因診斷率的提高、遺傳性視網膜疾病臨床試驗的擴展、各種孤兒藥舉措的支持，以及眼科基因療法的創新，這些創新增強了早期診斷和疾病修正治療的潛力。

市場動態

全球視錐細胞和視桿細胞營養不良症市場正受到基因治療產品線擴張、基因檢測在疾病早期診斷中的應用日益廣泛以及製藥​​公司在罕見遺傳性視網膜疾病精準醫療領域研發投入增加的推動，從而促進了標靶治療和創新方法的開發。新技術如次世代定序（NGS）普及、多項孤兒藥激勵政策的訂定以及綜合細胞和基因治療產品組合的持續獎勵開發，都增強了視錐細胞和視桿細胞營養不良症早期檢測和治療的潛力，並加速了疾病修正治療的研發。

然而，市場面臨許多限制因素，包括患者群體中潛在基因突變的高度異質性、高成本，以及從有限的視錐細胞-視桿細胞營養不良（CRD）患者群體中收集足夠規模的隊列樣本用於臨床試驗的複雜性。儘管如此，CRISPR技術的進步、針對有效生物標記的研究不斷深入，以及生物製藥公司與公共研究機構之間日益增多的策略合作，都將為視錐細胞-視桿細胞營養不良市場帶來新的成長機會。

本報告的主要特點

• 本報告揭示了各個細分市場的潛在商機，並描述了該市場中一系列有吸引力的投資提案。
• 此外，它還提供了有關市場促進因素和限制因素、機會、新產品發布和批准、市場趨勢、區域展望以及主要公司採取的競爭策略的重要見解。
• 本節根據各種參數（公司概況、產品系列、主要趨勢、財務表現、策略等）對全球視錐細胞和視桿細胞營養不良市場的主要公司進行介紹。
• 本報告中的見解將使負責人和企業經營團隊能夠就未來的產品發布、技術更新、市場擴張和行銷策略做出明智的決策。
• 《全球錐桿細胞營養不良市場》報告面向該行業的眾多相關人員，包括投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
• 相關人員可以透過分析全球視錐細胞和視桿細胞營養不良市場中使用的各種策略矩陣來促進決策。

目錄

第1章：分析目標與假設

• 分析目的
• 先決條件
• 簡稱

第2章 市場展望

• 報告說明
  • 市場定義和範圍
• 執行摘要

第3章：市場動態、監管與趨勢分析

• 市場動態
• 影響分析
• 主要亮點
• 監管趨勢
• 按疾病分類的市場上市與核准情況
• PEST分析
• 波特五力分析
• 市場機遇
• 監管趨勢
• 產業趨勢

第4章：全球視錐細胞和視桿細胞營養不良市場：依疾病類型分類（2021-2033 年）

• 視錐細胞和視桿細胞營養不良
• 視桿細胞和視錐細胞營養不良

第5章：全球視錐細胞和視桿細胞營養不良市場：依診斷方法分類（2021-2033 年）

• 基因檢測
• 視網膜電圖（ERG）
• 光學同調斷層掃描（OCT）
• 眼底螢光（FAF）
• 其他

第6章：全球視錐細胞和視桿細胞營養不良市場：依治療方法分類（2021-2033 年）

• 支持性護理
• 藥物治療
• 基因治療
• 細胞療法
• 視網膜人工替代物和視覺輔助設備

第7章 全球視錐細胞和視桿細胞營養不良市場：按最終用戶分類（2021-2033 年）

• 醫院
• 眼科診所
• 專業眼科中心
• 研究機構
• 其他

第8章：全球視錐細胞和視桿細胞營養不良市場：按地區分類（2021-2033 年）

• 北美洲
  • 美國
  • 加拿大
• 拉丁美洲
  • 巴西
  • 阿根廷
  • 墨西哥
  • 其他拉丁美洲國家
• 歐洲
  • 德國
  • 英國
  • 西班牙
  • 法國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國
  • ASEAN
  • 其他亞太國家
• 中東
  • 海灣合作理事會國家
  • 以色列
  • 其他中東國家
• 非洲
  • 南非
  • 北非
  • 中非

第9章 競爭情勢

• SparingVision
• Beacon Therapeutics
• Nanoscope Therapeutics
• JCyte
• MeiraGTx
• Spark Therapeutics
• Ocugen, Inc.
• ProQR Therapeutics
• Alkeus Pharmaceuticals
• BlueRock Therapeutics

第10章 分析師建議

• 機會分析
• 分析師意見
• Coherent Opportunity Map (COM)

第11章 參考文獻與分析方法

• 參考
• 分析方法
• 關於 Coherent Market Insights

Cone Rod Dystrophy Market is estimated to be valued at USD 148.6 Mn in 2026 and is expected to reach USD 237.8 Mn by 2033, growing at a compound annual growth rate (CAGR) of 7% from 2026 to 2033.

Cone-rod dystrophy (CRD) is a group of rare inherited disorders in which the retina's cones photoreceptors deteriorate followed by rods, leading to the gradual loss of central and color vision and visual acuity, then loss of peripheral vision. Cone-rod dystrophy can result from a wide range of mutations affecting over 30 genes, such as the ABCA4, RPGR and CRX gene, and is inherited in autosomal dominant, recessive or X-linked patterns. With an estimated worldwide prevalence between 1 in 30,000 and 1 in 40,000 people, CRD represents an area of significant unmet need.

The cone rod dystrophy market comprises several segments including diagnostic, supportive care and low vision rehabilitation technologies, in addition to nascent but advancing gene and cell therapies that represent novel advanced treatment options. The market growth is stimulated by rising rates of genetic diagnosis, expanded inherited retinal disease clinical trials, support from various orphan drug initiatives and innovation in ocular gene therapies that enhance chances of prompt diagnosis and disease-modifying therapies for patients.

Market Dynamics

The global cone rod dystrophy market is driven by expanding gene therapies pipeline, growing adoption of genetic testing for early diagnosis of disease, and increasing R&D investment by the pharmaceutical companies in the development of targeted therapy and innovative approaches in the area of precision medicine in rare inherited retinal disorders. The rise in adoption of novel technologies like next-generation sequencing, the launch of several orphan drug incentives and ongoing clinical development of a comprehensive portfolio of cell and gene therapies have boosted the potential of early identification and treatment of cone rod dystrophy and supported the accelerated introduction of disease-modifying therapeutics.

However, a number of constraints are present in the market, such as high heterogeneity of the underlying genetic mutations in the disease population, high costs of development and treatment and the complexities involved in assembling appropriate cohort size samples from the limited CRD population in clinical trials. Nevertheless, developments such as CRISPR-based technology, broadening research in identifying effective biomarkers, along with expanding strategic alliances amongst biopharmaceutical firms and public research bodies will offer new opportunities for growth in cone rod dystrophy market.

Key Features of the Study

• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global cone rod dystrophy market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include SparingVision, Beacon Therapeutics, Nanoscope Therapeutics, JCyte, MeiraGTx, Spark Therapeutics, Ocugen, Inc., ProQR Therapeutics, Alkeus Pharmaceuticals, and BlueRock Therapeutics
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global cone rod dystrophy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global cone rod dystrophy market

Market Segmentation

• Disease Type Insights (Revenue, USD Mn, 2021 - 2033)
• Cone-Rod Dystrophy
• Rod-Cone Dystrophy
• Diagnosis Insights (Revenue, USD Mn, 2021 - 2033)
• Genetic Testing
• Electroretinography (ERG)
• Optical Coherence Tomography (OCT)
• Fundus Autofluorescence (FAF)
• Others
• Treatment Insights (Revenue, USD Mn, 2021 - 2033)
• Supportive Care
• Pharmacological Therapy
• Gene Therapy
• Cell Therapy
• Retinal Prostheses and Visual Aids
• End User Insights (Revenue, USD Mn, 2021 - 2033)
• Hospitals
• Ophthalmology Clinics
• Specialty Eye Centers
• Research Institutes
• Others
• Regional Insights (Revenue, USD Mn, 2021 - 2033)
• North America
  • U.S.
  • Canada
• Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
• Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
• Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
• Africa
  • South Africa
  • North Africa
  • Central Africa
• Key Players Insights
• SparingVision
• Beacon Therapeutics
• Nanoscope Therapeutics
• JCyte
• MeiraGTx
• Spark Therapeutics
• Ocugen, Inc.
• ProQR Therapeutics
• Alkeus Pharmaceuticals
• BlueRock Therapeutics

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Global Cone Rod Dystrophy Market, By Disease Type
  • Global Cone Rod Dystrophy Market, By Diagnosis
  • Global Cone Rod Dystrophy Market, By Treatment
  • Global Cone Rod Dystrophy Market, By End User
  • Global Cone Rod Dystrophy Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
• Impact Analysis
• Key Highlights
• Regulatory Scenario
• Disease Type Launches/Approvals
• PEST Analysis
• PORTER's Analysis
• Market Opportunities
• Regulatory Scenario
• Industry Trends

4. Global Cone Rod Dystrophy Market, By Disease Type, 2021-2033, (USD Mn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022 - 2033
  • Segment Trends
• Cone-Rod Dystrophy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
• Rod-Cone Dystrophy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)

5. Global Cone Rod Dystrophy Market, By Diagnosis, 2021-2033, (USD Mn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022 - 2033
  • Segment Trends
• Genetic Testing
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
• Electroretinography (ERG)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
• Optical Coherence Tomography (OCT)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
• Fundus Autofluorescence (FAF)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)

6. Global Cone Rod Dystrophy Market, By Treatment, 2021-2033, (USD Mn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022 - 2033
  • Segment Trends
• Supportive Care
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
• Pharmacological Therapy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
• Gene Therapy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
• Cell Therapy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
• Retinal Prostheses and Visual Aids
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)

7. Global Cone Rod Dystrophy Market, By End User, 2021-2033, (USD Mn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022 - 2033
  • Segment Trends
• Hospitals
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
• Ophthalmology Clinics
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
• Specialty Eye Centers
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
• Research Institutes
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)

8. Global Cone Rod Dystrophy Market, By Region, 2021 - 2033, Value (USD Mn)

• Introduction
  • Market Share (%) Analysis, 2026, 2029 & 2033, Value (USD Mn)
  • Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Mn)
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Diagnosis, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Treatment, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Diagnosis, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Treatment, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Diagnosis, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Treatment, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Diagnosis, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Treatment, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Diagnosis, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Treatment, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
    • GCC Countries
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Diagnosis, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Treatment, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)
  • Market Size and Forecast, By Country/Region, 2021 - 2033, Value (USD Mn)
    • South Africa
    • North Africa
    • Central Africa

9. Competitive Landscape

• SparingVision
  • Company Highlights
  • Disease Type Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Beacon Therapeutics
  • Company Highlights
  • Disease Type Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Nanoscope Therapeutics
  • Company Highlights
  • Disease Type Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• JCyte
  • Company Highlights
  • Disease Type Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• MeiraGTx
  • Company Highlights
  • Disease Type Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Spark Therapeutics
  • Company Highlights
  • Disease Type Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Ocugen, Inc.
  • Company Highlights
  • Disease Type Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• ProQR Therapeutics
  • Company Highlights
  • Disease Type Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Alkeus Pharmaceuticals
  • Company Highlights
  • Disease Type Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• BlueRock Therapeutics
  • Company Highlights
  • Disease Type Portfolio
  • Key Developments
  • Financial Performance
  • Strategies

10. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

11. References and Research Methodology

• References
• Research Methodology
• About us